Skip to main content
OpenTrials

Clinical trial condition

Ovarian Clear Cell Adenocarcinoma

Explore clinical trials studying Ovarian Clear Cell Adenocarcinoma. Study availability and eligibility vary by location and protocol.

21 public trials 3 recruiting studies
Refine in advanced search Browse all conditions

Ovarian Clear Cell Adenocarcinoma trial results

Recruiting

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

NCT04575935

Conditions
Adnexal Diseases, Advanced Ovarian Carcinoma, Endocrine Gland Neoplasms, +39 more
Locations
  • University of Miami Miller School of Medicine-Sylvester Cancer Center Miami, Florida, United States
  • Cleveland Clinic Foundation - Florida Weston, Florida, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
View all 19 locations
View Trial Details
Active, not recruiting

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02446600

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +27 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
  • Alaska Women's Cancer Care Anchorage, Alaska, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
View all 356 locations
View Trial Details
Active, not recruiting

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

NCT02502266

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +29 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Alaska Women's Cancer Care Anchorage, Alaska, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
View all 398 locations
View Trial Details
Active, not recruiting

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

NCT00565851

Conditions
Adenocarcinoma, Adenocarcinoma, Clear Cell, Adenocarcinoma, Mucinous, +51 more
Locations
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
  • Alaska Oncology and Hematology LLC Anchorage, Alaska, United States
View all 709 locations
View Trial Details
Completed

Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT00951496

Conditions
Adnexal Diseases, Brenner Tumor, Endocrine System Diseases, +55 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Saint Joseph's Hospital and Medical Center Phoenix, Arizona, United States
View all 503 locations
View Trial Details
Completed

Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02713386

Conditions
Adnexal Diseases, FIGO Stage III Ovarian Cancer 2014, FIGO Stage IIIA Ovarian Cancer 2014, +35 more
Locations
  • CTCA at Western Regional Medical Center Goodyear, Arizona, United States
  • Sutter Auburn Faith Hospital Auburn, California, United States
  • UCLA / Jonsson Comprehensive Cancer Center Los Angeles, California, United States
  • Sutter Roseville Medical Center Roseville, California, United States
View all 110 locations
View Trial Details
Completed

Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)

NCT03648489

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +22 more
Locations
  • Charité Universitätsmedizin Berlin Berlin, Germany
  • Universitätsklinikum Carl Gustav Carus Dresden Dresden, Germany
  • KEM Kliniken Essen-Mitte Essen, Germany
  • Furness General Hospital Barrow in Furness, Cumbria, United Kingdom
View all 15 locations
View Trial Details

Related conditions